Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
OBJECTIVE
To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach.


METHODS
A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years). Prednisolone (60 mg/m(2) per day in three divided doses) was administered both orally and intravenously, and samples were obtained on several days during the initial 5 weeks of remission induction therapy. Unbound plasma concentrations ( n=288) were determined by HPLC and ultrafiltration. Nonlinear mixed-effects modeling (WinNonMix version 2.0.1) was used to estimate the pharmacokinetic parameters, to identify significant covariates, and to estimate the protein binding parameters.


RESULTS
Prednisolone showed complete oral bioavailability. The median unbound clearance (32 l/h per m(2)) was lower, and the half-life (3.6 h) longer than previously reported in childhood ALL. Body weight was a significant covariate for the central and peripheral volumes of distribution resulting in interindividual variabilities of 50% and 42%. Including body surface area as a covariate for clearance decreased the interindividual variability to 14%. The estimated areas under the unbound plasma concentration-time curves showed less than twofold variation among patients, and a residual variability of 20% indicated that the pharmacokinetic parameters remained stable during induction therapy. The estimated protein binding parameters were comparable to, but slightly lower than, previously published values and independent of the albumin concentration.


CONCLUSIONS
The study showed complete oral bioavailability, a lower unbound clearance and a longer half-life for prednisolone than previously reported in childhood ALL. Plasma protein binding was independent of the albumin concentration. Due to the small inter- and intraindividual variations in the pharmacokinetic parameters, body surface area-based dosing is sufficient to obtain similar systemic exposure among patients.
Petersen
Kamilla B
KB
Department of Pharmaceutics, The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark.
Jusko
William J
WJ
Rasmussen
Mette
M
Schmiegelow
Kjeld
K
D000284:Administration, Oral; D000293:Adolescent; D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D001772:Blood Cell Count; D001798:Blood Proteins / Q000378:metabolism; D001830:Body Surface Area; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D011153:Population; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism*; D011239:Prednisolone / Q000097:blood / Q000493:pharmacokinetics*; D011485:Protein Binding; D014462:Ultrafiltration
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D011239:Prednisolone